



## Idarucizumab

Revised: December 3, 2018.

CASRN: 1362509-93-0

## Drug Levels and Effects

### Summary of Use during Lactation

No information is available on the clinical use of idarucizumab during breastfeeding. Because it is a large protein molecule with a molecular weight of about 48,000, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract.

### Drug Levels

*Maternal Levels.* Relevant published information was not found as of the revision date.

*Infant Levels.* Relevant published information was not found as of the revision date.

### Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

### Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

## Substance Identification

### Substance Name

Idarucizumab

### CAS Registry Number

1362509-93-0

### Drug Class

Breast Feeding

**Disclaimer:** Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site .

## Lactation

Antibodies, Immunoglobulin Fragments